Brian D. Weiss

Hematology | Oncology
705 Riley Hospital Dr
Indianapolis, IN 46202

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications

Single-cell and spatial omics reveals region-specific plasticity and therapeutic vulnerabilities in metastatic high-risk neuroblastoma.

Single-cell and spatial omics reveals region-specific plasticity and therapeutic vulnerabilities in metastatic high-risk neuroblastoma.

Journal: Science advances
Published: July 17, 2026

Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.

Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.

Journal: Neuro-oncology advances
Published: April 27, 2026

Long-Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1-Associated Plexiform Neurofibromas.

Long-Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1-Associated Plexiform Neurofibromas.

Journal: Pediatric blood & cancer
Published: April 02, 2026

Single-cell and Spatial Omics Reveals Region-Specific Plasticity and Therapeutic Vulnerabilities in Metastatic High-Risk Neuroblastoma.

Single-cell and Spatial Omics Reveals Region-Specific Plasticity and Therapeutic Vulnerabilities in Metastatic High-Risk Neuroblastoma.

Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025

Acute Distal Limb Ischemia After Large-Bore Arterial Access: An Expert Review and Consensus Recommendations.

Acute Distal Limb Ischemia After Large-Bore Arterial Access: An Expert Review and Consensus Recommendations.

Journal: The Annals of thoracic surgery
Published: October 26, 2025

Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study.

Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study.

Journal: Transplantation and cellular therapy
Published: August 20, 2025

Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 23, 2025

Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.

Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 19, 2025

Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma: A Children's Oncology Group Report.

Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma: A Children's Oncology Group Report.

Journal: JAMA network open
Published: February 14, 2025

Tailored ECMO for Respiratory Failure: Moving From Off-the-Rack to Bespoke.

Tailored ECMO for Respiratory Failure: Moving From Off-the-Rack to Bespoke.

Journal: ASAIO journal (American Society for Artificial Internal Organs : 1992)
Published: December 02, 2024

The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma.

The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma.

Journal: Human genetics
Published: November 25, 2024

A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma.

A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma.

Journal: Cancer
Published: October 03, 2024
Showing 1-12 of 72

Last Updated: 09/26/2026